Academic literature on the topic 'Employee advisor'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Employee advisor.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Employee advisor"
1
Daar, Eric, Edwin DeJesus, Peter Ruane, et al. "Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results." Open Forum Infectious Diseases 4, suppl_1 (2017): S735. http://dx.doi.org/10.1093/ofid/ofx180.003.
Full textAbstract:
Abstract Background Boosted protease inhibitor regimens (bPIs) are effective and often used in HIV-infected individuals with difficulties with adherence, but they can have drug–drug interactions and GI adverse effects. Bictegravir (B), a novel, potent integrase strand transfer inhibitor with a high barrier to resistance and low potential for drug–drug interactions, was coformulated with the recommended nucleoside reverse transcriptase inhibitor backbone emtricitabine (FTC)/tenofovir alafenamide (F/TAF) and demonstrated high efficacy and tolerability in randomized studies in treatment-naïve adults. This randomized Phase 3 study assesses efficacy and safety of switching to B/F/TAF from a multi-tablet regimen containing a bPI. Methods HIV-infected adults suppressed on regimens of boosted atazanavir (ATV) or darunavir (DRV) + abacavir/lamivudine (ABC/3TC) or FTC/tenofovir disoproxil fumarate (TDF) were randomized 1:1 to continue their current bPI regimen or switch to open-label coformulated B/F/TAF (50/200/25 mg) once daily. Primary endpoint was proportion with HIV-1 RNA ≥50 copies/mL (c/mL) at W48 (FDA snapshot). Noninferiority was assessed through 95.002% confidence intervals (CI) using a margin of 4%. Secondary endpoints included proportion with HIV-1 RNA <50 c/mL and safety measures at W48. Results A total of 577 participants were randomized and treated with B/F/TAF (n = 290) or current bPI regimens (n = 287): 17% women, 26% Black, median age 48 years. Most were receiving a bPI with FTC/TDF (85%) at screening. At W48, switching to B/F/TAF was noninferior to continuing bPI with 1.7% in each group having HIV-1 RNA ≥50 c/mL (difference −0.0%; 95.002% CI −2.5% to 2.5%, P = 1.00); the proportion with HIV-1 RNA <50 c/mL was 92.1% in B/F/TAF vs. 88.9% in bPI. No participant on B/F/TAF developed resistance to study drugs. One participant on DRV/ritonavir + ABC/3TC developed a treatment-emergent L74V mutation. Incidence of grade 3 or 4 AEs was similar (B/F/TAF 4%, bPI regimens 6%). No renal discontinuations or tubulopathy cases occurred with B/F/TAF. Conclusion Adults switching to B/F/TAF from a boosted PI maintained high rates of virologic suppression without resistance. B/F/TAF was safe and well tolerated. Disclosures E. Daar, Bristol-Myers Squibb: Consultant, Consulting fee. Gilead Sciences, Inc.: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. Janssen: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. Merck: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. Teva Pharmaceuticals: Consultant and Scientific Advisor, Consulting fee. ViiV: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. E. DeJesus, Abbott Laboratories; Achillion Pharmaceuticals, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffmann LaRoche, Idenix, Janssen, Merck, Pfizer, Sangamo, Taimed, Tobira, and Vertex: Grant Investigator, Research grant. Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Vertex: Scientific Advisor, Consulting fee. P. Ruane, Gilead: Investigator, Scientific Advisor and Shareholder, Consulting fee and Research support. Merck: Speaker’s Bureau, Speaker honorarium. Boehringer: Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium. Janssen: Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium. Abbott: Investigator, Scientific Advisor and Speaker’s Bureau, Research support and Speaker honorarium. Idenix: Investigator, Research support. ViiV: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium. BMS: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium. G. Crofoot, Gilead: Investigator and Scientific Advisor, Advisory honorarium and Research grant. ViiV: Investigator and Scientific Advisor, Advisory honorarium, Research grant and Research support. C. Creticos, Thera Technologies and ViiV Healthcare: Scientific Advisor, Consulting fee. Gilead sciences, Merck, and ViiV Healthcare: Investigator, Research support. Pfizer: Speaker’s Bureau, Speaker honorarium. J. K. Rockstroh, Abbvie: Consultant and Investigator, Consulting fee and Speaker honorarium. Gilead: Consultant, Investigator and Scientific Advisor, Consulting fee and Speaker honorarium. ViiV: Scientific Advisor, Consulting fee. Janssen: Investigator and Speaker at educational event, Speaker honorarium. J. M. Molina, Gilead, ViiV, Merck, Janssen, BMS and TEVA: Scientific Advisor, Speaker honorarium. Y. P. Liu, Gilead: Employee and Shareholder, Salary and Shareholder. K. Andreatta, Gilead: Employee and Shareholder, Salary and Shareholder. H. Graham, Gilead Sciences: Employee and Shareholder, Salary. A. Cheng, Gilead: Employee and Shareholder, Salary. H. Martin, Gilead Sciences: Employee, Salary. E. Quirk, Gilead: Employee and Shareholder, Salary
2
Tica, Jelena, Javier Ruiz Guiñazú, Charles P. Andrews, et al. "119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated." Open Forum Infectious Diseases 7, Supplement_1 (2020): S187—S188. http://dx.doi.org/10.1093/ofid/ofaa439.429.
Full textAbstract:
Abstract Background RSV is a common cause of respiratory acute illness in older adults (OA). We evaluated safety and reactogenicity of RSVPreF3 candidate vaccine in young adults (YA) and OA. Methods In this phase I/II, placebo-controlled, multi-country trial (NCT03814590), YA aged 18–40 years were randomized 1:1:1:1 and received 2 doses of Low-, Medium- or High-dose of RSVPreF3 non-adjuvanted vaccine, or placebo, 2 months apart. Following favorable safety evaluation, a staggered enrolment with 2 steps followed in OA aged 60–80 years, who were randomized 1:1:1:1:1:1:1:1:1:1 to receive 1 of the 9 RSV vaccine formulations containing Low-, Medium- or High-dose of RSVPreF3 non-adjuvanted or adjuvanted with AS01E or AS01B, or placebo (same schedule). Safety/reactogenicity up to 1 month post-dose 1 are reported here. Results Exposed set was comprised of 48 YA and 1005 OA. Within 7 days post-dose 1, any solicited/unsolicited adverse event (AE) ranged from 58.3% to 83.3% across YA vaccinees (placebo YA: 58.3%) and from 29.9% to 84.2% across OA vaccinees (placebo OA: 33.7%) (Fig 1). Pain was the most common solicited local AE, being reported in ≤ 58.3% of YA (placebo YA: 0.0%) and at higher rates in the adjuvanted groups (≤ 75.7%) vs non-adjuvanted groups of OA (≤ 14.1%) and placebo OA (4.1%) (Fig 2A). Of solicited general AEs, fatigue (YA: ≤ 41.7% in vaccinees vs 50.0% in placebo; OA: ≤ 48.5% in vaccinees vs 16.3% in placebo) and headache (YA: ≤ 33.3% in vaccinees vs 16.7% in placebo; OA: ≤ 27.7% in vaccinees vs 8.2% in placebo) were most commonly reported (Fig 2B), while fever ≥ 38.0 °C was observed in ≤ 3.0% of OA vaccinees (placebo OA: 0.0%). Grade 3 solicited local and general AEs were observed in OA only, with erythema (≤ 4.9% in vaccinees vs 0.0% in placebo) and fatigue (≤ 2.0% in vaccinees vs 1.0% in placebo) being most common (Fig 2). No serious AEs (SAEs) were reported in YA. A number of 11 OA reported a SAE within 1 month post-dose 1, but none was fatal or assessed as vaccine-related. No clinically significant abnormalities occurred in hematological/biochemical parameters in any group. Figure 1. Percentage of participants presenting at least one type of solicited/unsolicited adverse event (AE) within 7 days post-dose 1 Figure 2. Percentage of participants with at least one type of solicited adverse event (AE) within 7 days post-dose 1 Conclusion First dose of RSVPreF3 candidate vaccine is well tolerated. AE rates tended to be higher after AS01B-adjuvanted formulations compared to other vaccine formulations. No safety concerns were raised. Funding GlaxoSmithKline Biologicals SA Disclosures Jelena Tica, PhD, GSK group of companies (Employee, Shareholder) Javier Ruiz Guiñazú, MD MSc, GSK group of companies (Employee, Shareholder) Charles P. Andrews, MD, GSK group of companies (Scientific Research Study Investigator) Charles Fogarty, MD, GSK group of companies (Grant/Research Support) Edward Kerwin, MD, Amphastar (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)AstraZeneca (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Boehringer Ingelheim (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Chiesi (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Cipla (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)GSK group of companies (Employee, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Mylan (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Novartis (Employee, Advisor or Review Panel member, Research Grant or Support, Speaker’s Bureau)other around 40 pharmaceutical companies (Other Financial or Material Support, conducted multicenter clinical research trials)Pearl (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Sunovion (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Theravance (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau) Isabel Leroux-Roels, MD PhD, GSK group of companies (Scientific Research Study Investigator) Corinne Vandermeulen, MD PhD, GSK group of companies (Other Financial or Material Support, My university only received Grant/Research Support) Marie-Pierre David, MSc, GSK group of companies (Employee, Shareholder) Nancy Dezutter, PhD, PharmD, RPh, GSK group of companies (Employee, Shareholder) Laurence Fissette, MSc, GSK group of companies (Employee) Juliane Koch, MD, GSK group of companies (Employee, Shareholder) Narcisa Mesaros, MD, MSc, GSK group of companies (Employee)
3
Guiñazú, Javier Ruiz, Jelena Tica, Charles P. Andrews, et al. "121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic." Open Forum Infectious Diseases 7, Supplement_1 (2020): S188—S189. http://dx.doi.org/10.1093/ofid/ofaa439.431.
Full textAbstract:
Abstract Background RSV causes significant disease burden in older adults, since reinfections are common and may lead to severe disease presentations while only supportive treatment is available. We present immunogenicity of different formulations of an investigational vaccine (RSVPreF3) in young and older adults. Methods This is a phase I/II, placebo-controlled, multi-country trial (NCT03814590). Healthy adults aged 18–40 years were randomized 1:1:1:1 to receive 2 doses of either Low-, Medium- or High-dose of RSVPreF3 non-adjuvanted vaccine or placebo, 2 months apart. Following favorable safety outcomes, adults aged 60–80 years were randomized 1:1:1:1:1:1:1:1:1:1 in a 2-step staggered manner to receive 1 of the 9 RSV vaccine formulations containing Low-, Medium- or High-dose of RSVPreF3, non-adjuvanted or adjuvanted with AS01E or AS01B, or placebo (same schedule). Humoral and cellular-mediated immune responses are assessed before and after each dose; results up to 1 month post-dose 1 are shown here. Results Of 48 adults aged 18–40 years and 1005 aged 60–80 years included in the exposed set, 42 and 933, respectively, were part of per-protocol set at 1 month post-dose 1. RSVPreF3 IgG geometric mean antibody concentrations were 8.4–13.5 and 7.2–12.8 fold-higher at 1 month post-dose 1 vs baseline in the 18–40- and 60–80-year-old vaccinees, respectively (Fig 1A). RSV-A neutralization activity significantly increased in all RSV vaccinees, geometric mean antibody titers being 7.5–13.7 and 5.6–9.9 fold-higher in 18–40- and 60–80-year-olds, respectively, at 1 month post-dose 1 vs baseline (Fig 1B). Geometric mean ratios of the fold increase between RSVPreF3 IgG antibody concentrations and RSV-A neutralizing antibody titers ranged between 0.9–1.1 in 18–40-year-old and 1.3–1.5 in 60–80-year-old vaccinees. A robust RSVPreF3-specific CD4+ T-cell response was elicited at 1 month post-dose 1 vs baseline in both 18–40- and 60–80-year-olds (Fig 2). Figure 1. RSVPreF3 IgG geometric mean antibody concentrations (GMCs, enzyme-linked immunosorbent assay, panel A), RSV-A neutralizing geometric mean antibody titers (GMTs, neutralization assay, panel B) Figure 2. RSVPreF3-specific CD4+ T-cells identified as expressing ≥2 markers among IL2, CD40L, TNF-□, IFN-□ (intracellular cytokine staining assay) Conclusion One dose of RSVPreF3 candidate vaccine boosted humoral and cellular immune responses in all vaccinees. In older adults, higher humoral response, mostly neutralizing, was observed with increased RSVPreF3 antigen dosage and a tendency of higher cellular response was observed after adjuvanted formulations. Funding GlaxoSmithKline Biologicals SA Disclosures Javier Ruiz Guiñazú, MD MSc, GSK group of companies (Employee, Shareholder) Jelena Tica, PhD, GSK group of companies (Employee, Shareholder) Charles P. Andrews, MD, GSK group of companies (Scientific Research Study Investigator) Charles Fogarty, MD, GSK group of companies (Grant/Research Support) Edward Kerwin, MD, Amphastar (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)AstraZeneca (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Boehringer Ingelheim (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Chiesi (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Cipla (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)GSK group of companies (Employee, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Mylan (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Novartis (Employee, Advisor or Review Panel member, Research Grant or Support, Speaker’s Bureau)other around 40 pharmaceutical companies (Other Financial or Material Support, conducted multicenter clinical research trials)Pearl (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Sunovion (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau)Theravance (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau) Isabel Leroux-Roels, MD PhD, GSK group of companies (Scientific Research Study Investigator) Corinne Vandermeulen, MD PhD, GSK group of companies (Other Financial or Material Support, My university only received Grant/Research Support) Marie-Pierre David, MSc, GSK group of companies (Employee, Shareholder) Nancy Dezutter, PhD, PharmD, RPh, GSK group of companies (Employee, Shareholder) Nathalie De Schrevel, PhD, GSK group of companies (Employee) Laurence Fissette, MSc, GSK group of companies (Employee) Narcisa Mesaros, MD, MSc, GSK group of companies (Employee)
4
Mills, Anthony, Gary J. Richmond, Cheryl Newman, et al. "116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study." Open Forum Infectious Diseases 7, Supplement_1 (2020): S186—S187. http://dx.doi.org/10.1093/ofid/ofaa439.426.
Full textAbstract:
Abstract Background Long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) injectable suspensions have demonstrated efficacy in phase III studies. POLAR assessed antiviral activity and safety of CAB LA+RPV LA, administered every 2 mos (Q2M), in HIV-1 infected, antiretroviral therapy–experienced adults who completed LATTE and received once-daily oral CAB30mg+RPV25mg treatment. Methods POLAR is a phase IIb, multicenter, open-label, rollover study in 97 virologically suppressed, HIV-infected adults. LATTE participants who completed ≥312 weeks on study, with plasma HIV-1RNA< 50c/mL at screening, were eligible for POLAR and offered the option to switch to CAB LA+RPV LA Q2M or to the oral fixed dose combination of dolutegravir (DTG)/rilpivirine (RPV) once daily, for continued maintenance of HIV-1RNA suppression. 90 participants chose CAB LA+RPV LA and 7 participants chose oral DTG/RPV. The primary outcome measure was proportion of participants with plasma HIV-1RNA≥50c/mL after 12 mos (M12) of therapy. Safety and laboratory measures were assessed throughout the study. Participants selecting LA treatment completed satisfaction and quality-of-life questionnaires at Day 1, M6, and M12. Results At M12, no participant had HIV-1RNA≥50c/mL or protocol defined virologic failure (confirmed plasma HIV-1RNA > 200c/mL). Excluding injection-site reactions (ISRs), nasopharyngitis (11%), upper respiratory tract infection (11%), diarrhea (10%), and pyrexia (10%) were the most commonly reported adverse events (AEs) in the Q2M arm. 10% (9/90) of Q2M participants reported AEs ≥grade 3; 0 were drug related. 2% (2/90) of Q2M participants had AEs leading to withdrawal. 6% (5/90) of participants reported serious AEs (1 considered drug-related). Over 12 mo, 1534 injections were administered; 463 ISRs were reported (30%; all grade 1/2 [84%/16%]); resolution of ISRs occurred after a median of 3 days. Minimal changes in lab parameters were observed in participants across 12 mo. 88% of participants who received LA therapy preferred CAB LA+RPV LA vs oral therapy. Table 1 Table 2 Conclusion CAB LA+RPV LA, administered Q2M, resulted in durable virologic suppression, an acceptable tolerability profile, and high levels of participant satisfaction over the first 12 mo of treatment in POLAR. Disclosures Anthony Mills, MD, Gilead (Grant/Research Support, Advisor or Review Panel member)Janssen Pharmaceutica (Grant/Research Support, Advisor or Review Panel member)Merck (Grant/Research Support, Advisor or Review Panel member)Shionogi (Grant/Research Support)ViiV Healthcare (Grant/Research Support, Advisor or Review Panel member) Gary J. Richmond, MD, FACP, FCCP, Gilead (Scientific Research Study Investigator)TaiMed (Scientific Research Study Investigator)Viv (Scientific Research Study Investigator) Cheryl Newman, MD, Gilead (Grant/Research Support)GlaxoSmithKline (Grant/Research Support, Speaker’s Bureau)ViiV Healthcare (Research Grant or Support, Speaker’s Bureau) Olayemi Osiyemi, M.D, GlaxoSmithKline (Advisor or Review Panel member, Speaker’s Bureau)ViiV Healthcare (Advisor or Review Panel member, Speaker’s Bureau) Jerry Cade, MD, Gilead (Consultant, Research Grant or Support, Speaker’s Bureau)Janssen Pharmaceutica (Consultant)Merck (Consultant, Research Grant or Support, Speaker’s Bureau)ViiV Healthcare (Consultant, Research Grant or Support) Cynthia Brinson, MD, Gilead (Advisor or Review Panel member, Speaker’s Bureau)ViiV Healthcare (Advisor or Review Panel member, Speaker’s Bureau) Nisha Andany, MD, MPH, FRCPC, Gilead Sciences (Scientific Research Study Investigator)GlaxoSmithKline (Scientific Research Study Investigator)Janssen (Scientific Research Study Investigator) David Margolis, MD, MPH, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Kenneth Sutton, MA, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Viviana Wilches, HBSc, MBiotech, GlaxoSmithKline (Employee, Shareholder) Jeremy Roberts, MSc, GSK (Employee) Cynthia C. McCoig, MD, ViiV Healthcare (Employee) Kati Vandermeulen, MSC, Janssen Pharmaceutica (Employee, Shareholder) William Spreen, PharmD, ViiV Healthcare (Employee, Shareholder)
5
Andrew, Melissa K., Joon Hyung Kim, Sean Matthews, et al. "5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies." Open Forum Infectious Diseases 7, Supplement_1 (2020): S2—S3. http://dx.doi.org/10.1093/ofid/ofaa417.004.
Full textAbstract:
Abstract Background Herpes zoster can negatively impact older adults’ health and quality of life. An adjuvanted recombinant zoster vaccine (RZV) has excellent vaccine efficacy (VE), including in older adults. Given that frailty is strongly associated with vulnerability to illness and adverse health outcomes, we studied how frailty impacts RZV VE, immunogenicity, reactogenicity, and safety. Methods In the ZOE-50 and ZOE-70 pivotal Phase 3 efficacy studies of RZV, 29,305 participants aged 50–96 received 2 doses of RZV vs. placebo in 1:1 randomization. In this secondary analysis (NCT03563183), a baseline frailty index (FI) was created retrospectively following previously validated methods using pre-existing comorbidities and patient reported outcomes. Participants were categorized as non-frail (FI≤ 0.08), pre-frail (FI=0.08–0.25) or frail (FI≥ 0.25) for stratified analyses. Results FI was calculated for 99.8% of participants included in this secondary analysis (n=26,976), and was balanced between RZV and placebo groups. 45.6% were pre-frail and 11.3% were frail. Mean age was 68.8 years; 58.1% were women. RZV VE against HZ was consistently above 90% for all frailty categories [non-frail: 95.8% (95%CI: 91.6–98.2), pre-frail: 90.4% (84.4–94.4), frail: 90.2% (75.4–97.0)]. The RZV group demonstrated robust antibody responses post-dose 2 across frailty categories. In the RZV group, the percentage of participants reporting solicited adverse events decreased with increasing frailty. Unsolicited medically attended visits and serious adverse events increased with frailty and were balanced between placebo and RZV groups. Conclusion The ZOE studies included older adults who were frail and pre-frail, and VE was high across frailty categories. Reactogenicity decreased with increasing frailty, and no safety concerns were identified in any frailty group. Disclosures Melissa K. Andrew, MD, PhD, MSc(Ph), GSK (Grant/Research Support, Research Grant or Support) Joon Hyung Kim, MD, GSK (Employee, Shareholder) Sean Matthews, MSc, GSK (Consultant) Christophe Dessart, MSc, GSK (Employee) myron J. levin, MD, Curevo (Advisor or Review Panel member)GlaxoSmithKline (Grant/Research Support, Advisor or Review Panel member)GlaxoSmithKline (Grant/Research Support, Advisor or Review Panel member)Merck Research Laboratories (Advisor or Review Panel member, GlaxoSmithKline)Merck Research Laboratories (Advisor or Review Panel member)Merck ResearchLaboratories (Advisor or Review Panel member) Lidia Oostvogels, MD, GSK (Shareholder) Megan Riley, PhD, GSK (Employee) Shelly McNeil, FRCPC, MD, GSK (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support, Other Financial or Material Support, honoraria for talks) Anne Schuind, MD, GSK (Employee, Other Financial or Material Support, own GSK stock options or restricted shares as part of renumeration) Desmond Curran, PhD, GSK (Employee, Shareholder)
6
Walmsley, Sharon, Gary Richmond, Fritz Bredeek, et al. "Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender." Open Forum Infectious Diseases 4, suppl_1 (2017): S427. http://dx.doi.org/10.1093/ofid/ofx163.1078.
Full textAbstract:
Abstract Background Switching to the 2-drug regimen (2DR) of DTG+RPV was proven non-inferior to continuing a suppressive PI-, INI- or NNRTI- based current antiretroviral regimen (CAR) at Week 48. This analysis evaluated the efficacy and safety of switching from CAR to DTG+RPV by age, race and gender subgroups. Methods Two identically designed, open-label, multicenter, global, phase III, non-inferiority studies compared the efficacy and safety of switching from a 3 or 4-drug CAR to DTG + RPV once daily in HIV-1-infected adults, with HIV-1 RNA<50 c/mL. Primary endpoint was proportion of patients with VL<50 c/mL at Wk48 using FDA Snapshot. Additional analysis were performed to summarize efficacy base on age, race and gender subgroups for each individual study and pooled. Results 1024 patients were randomized and exposed (DTG+RPV 513; CAR 511), across both studies. Treatment arms were well matched for demographic and baseline characteristics. Median age across both arms was 43.4 years, with 29% and 28% ≥ 50 years in DTG+RPV and CAR, respectively. 23% and 21% were female while 18% and 22% were non-white for DTG+RPV and CAR. For the pooled studies and for SWORD-1 and SWORD-2 individually, switching to DTG+RPV was non-inferior to CAR at Wk48. Similar response rates were observed in the DTG+RPV arm compared with CAR across subgroups (Table 1). More AEs were reported in the DTG+/RPV arm across all subgroups except Asian race; no unexpected AEs were identified for either drug. Conclusion Switch to a novel, once daily 2DR of DTG+RPV in patients with a suppressed viral load, was an effective and well tolerated treatment option across age, race, and gender subgroups which were consistent with overall results. Disclosures S. Walmsley, Merck: Board Member, Consultant, Grant Investigator, Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Grant recipient, Research grant and Speaker honorarium; ViiV Healthcare: Board Member, Consultant, Grant Investigator, Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Grant recipient, Research grant and Speaker honorarium; Gilead Sciences: Board Member, Consultant, Grant Investigator, Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Grant recipient, Research grant and Speaker honorarium; GSK: Board Member, Consultant, Grant Investigator, Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Grant recipient, Research grant and Speaker honorarium; Janssen: Board Member, Consultant, Grant Investigator, Investigator, Scientific Advisor and Speaker’s Bureau, Grant recipient, Research grant and Speaker honorarium; BMS: Grant Investigator, Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Grant recipient, Research grant and Speaker honorarium; G. Richmond, Viiv Healthcare: Investigator, Research support; 
 F. Bredeek, ViiV Healthcare: Investigator and Scientific Advisor, Consulting fee and Research support; M. Ramgopal, viiv: Investigator, Consulting fee; C. C. Hung, Gilead Sciences: Board Member and Speaker’s Bureau, Consulting fee and Speaker honorarium; ViiV: Board Member and Investigator, Consulting fee and Research support; Abbvie: Board Member and Investigator, Consulting fee and Research grant; Bristol-Myers Squibb: Investigator, Research support; Jassen: Board Member and Investigator, Consulting fee and Research support; E. Blair, ViiV Healthcare: Employee and Shareholder, Salary; L. Kahl, ViiV Healthcare: Employee and Shareholder, Salary; M. Underwood, ViiV Healthcare: Employee, Salary; K. Angelis, GlaxoSmithKline: Employee, Salary; K. Vandermeulen, Jansen: Employee, Salary; B. Wynne, ViiV Healthcare: Employee, Salary; M. Aboud, ViiV Healthcare: Employee, Salary
7
Orkin, Chloe, Jean-Michel Molina, Joel Gallant, et al. "Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults." Open Forum Infectious Diseases 4, suppl_1 (2017): S737—S738. http://dx.doi.org/10.1093/ofid/ofx180.009.
Full textAbstract:
Abstract Background EMERALD is evaluating the efficacy and safety of switching from bPI + FTC/TDF regimens (control) to D/C/F/TAF 800/150/200/10 mg in virologically suppressed, HIV-1-infected adults. We present Week 48 primary results. Method EMERALD (NCT02269917) is a randomized, active-controlled, open-label, international, multicenter, parallel-group, non-inferiority trial. Virologically suppressed (viral load [VL] < 50 c/mL for ≥2 months), HIV-1-infected adults were randomized (2:1) to switch to D/C/F/TAF or continue control. The FDA-stipulated primary endpoint was non-inferiority of D/C/F/TAF vs. control regarding % virologic rebound (confirmed VL ≥ 50 c/mL or premature discontinuations with last VL ≥ 50 c/mL) cumulative through Week 48 (4% margin). Result 1141 patients were randomized and treated (N = 763 D/C/F/TAF; N = 378 control); median age 46; 18% women; 76% white; 58% on >2 previous ARVs (prior to screening regimen); 15% with previous non-DRV virologic failure (VF). Virologic rebound through Week 48 was non-inferior for D/C/F/TAF (2.5%; n = 19) vs. control (2.1%; n = 8) (Δ0.4%, 95% CI: –1.5%; 2.2%; P < 0.001). Most rebounders (12/19 [63%] vs. 4/8 [50%]) resuppressed by Week 48 without change in therapy. Week 48 virologic suppression rates (VL < 50 c/mL; FDA Snapshot) were 94.9% vs. 93.7% (Δ1.2%, 95% CI: −1.7%;4.1%) and VF rates (VL ≥ 50 c/mL; Snapshot) were 0.8% vs. 0.5% (Δ0.3%, 95% CI: −0.7%;1.2%), with no discontinuations for VF. No resistance-associated mutations related to any study drug were observed. Adverse events (AEs) were similar between arms: AE-related discontinuations (1.4% vs. 1.3%); grade 3–4 AEs (6.8% vs. 8.2%); serious AEs (4.6% vs. 4.8%); and no deaths. Renal and bone parameters favored D/C/F/TAF vs. control. TC and LDL-C slightly favored control vs. D/C/F/TAF, with no clinically significant difference in TC/HDL-C ratio between arms (Table 1). Conclusion Percentage of virologic rebound after switching to D/C/F/TAF was non-inferior to control cumulative through Week 48, with high suppression rates (94.9%), no resistance development, better bone and renal safety parameters and similar TC/HDL-C ratio. D/C/F/TAF maintains the high genetic barrier to resistance of darunavir with the safety advantages of TAF, even in patients with a history of non-DRV VF. Disclosures C. Orkin, Janssen Pharmaceuticals: Grant Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. MSD: Grant Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. Viiv Healthcare: Grant Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. Gilead Sciences: Grant Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. J. M. Molina, Merck / Gilead: Scientific Advisor, Research grant. Janssen / Viiv / BMS / Teva: Scientific Advisor, Speaker honorarium. Gilead: Speaker’s Bureau, Speaker honorarium. J. Gallant, Janssen Therapeutics: Investigator, Research support. E. Negredo, Janssen: Board Member, Scientific Advisor and Speaker’s Bureau, Speaker honorarium. J. Gathe, Janssen: Consultant and Investigator, Research grant and Speaker honorarium. J. Eron, Janssen: Consultant and Grant Investigator, Consulting fee and Grant recipient. E. Van Landuyt, Janssen: Employee and Shareholder, Salary. E. Lathouwers, Janssen: Employee and Shareholder, Salary. V. Hufkens, Janssen: Employee and Shareholder, Salary. R. Petrovic, Janssen: Employee and Shareholder, Salary. M. Opsomer, Janssen: Employee and Shareholder, Salary.
8
Marty, Francisco M., Prashant Malhotra, Robert L. Gottlieb, et al. "72. Remdesivir vs Standard Care in Patients with Moderate covid-19." Open Forum Infectious Diseases 7, Supplement_1 (2020): S166—S167. http://dx.doi.org/10.1093/ofid/ofaa439.382.
Full textAbstract:
Abstract Background Remdesivir (RDV) shortens time to recovery time in patients with severe COVID-19. Its effect in patients with moderate COVID-19 remains unclear. Methods We conducted an open-label, phase 3 trial (NCT04252664) involving hospitalized patients with confirmed SARS-CoV-2 infection, evidence of pulmonary infiltrates, and oxygen saturation >94% on room air. Patients were randomly assigned 1:1:1 to receive up to 5d or 10d of RDV with standard of care (SoC), or SoC alone; patients could be discharged prior to completing per-protocol assigned treatment duration. RDV was dosed intravenously at 200 mg on d1, 100 mg daily thereafter. Patients were evaluated daily while hospitalized, and via telephone if discharged. The primary endpoint was clinical status on d11 assessed on a 7-point ordinal scale. Results regarding the primary endpoint are expected to be published before IDWeek 2020; we plan to present d28 results at the meeting. Results In total, 584 patients underwent randomization and started their assigned treatment (191, 5d RDV; 193, 10d RDV; 200, SoC). By d11, ³ 2 point improvement on the ordinal scale occurred in 70% of patients in the 5d arm, 65% in the 10d arm, and 61% in the SoC arm. Patients in the 5d RDV arm were significantly more likely to have an improvement in clinical status than those receiving SoC (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.09–2.48; P=0.017); OR of improvement for the 10d RDV arm compared to SoC was 1.31 (95% CI, 0.88–1.95]; p=0.183). This improvement in the 5-day arm over the SOC arm was noted from d6 through d11. We observed a peak of discharges corresponding with the assigned treatment duration of RDV, with increased discharges at d6 in the 5-day arm and at d11 in the 10-day arm. A worsening of clinical status of ≥ 1 point in the ordinal scale was observed more commonly in the SoC am (n=19, 10%) versus the 5d RDV (n=7, 4%) and 10d RDV (n=9, 5%). Conclusion RDV for up to 5 days was superior to SoC in improving the clinical status of patients with moderate COVID-19 by d11. We will report d28 outcomes at the meeting. Disclosures Francisco M. Marty, MD, Allovir (Consultant)Amplyx (Consultant)Ansun (Scientific Research Study Investigator)Avir (Consultant)Cidara (Scientific Research Study Investigator)F2G (Consultant, Scientific Research Study Investigator)Kyorin (Consultant)Merck (Consultant, Grant/Research Support, Scientific Research Study Investigator)New England Journal of Medicine (Other Financial or Material Support, Honorarium for Video)Regeneron (Consultant, Scientific Research Study Investigator)ReViral (Consultant)Scynexis (Scientific Research Study Investigator)Symbio (Consultant)Takeda (Scientific Research Study Investigator)United Medical (Consultant)WHISCON (Scientific Research Study Investigator) Prashant Malhotra, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Robert L. Gottlieb, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Karen T. Tashima, MD, Bristol-Myers Squibb (Research Grant or Support)Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator)GlaxoSmithKline (Research Grant or Support)Merck (Research Grant or Support)Tibotec (Research Grant or Support)Viiv Healthcare (Research Grant or Support) Massimo Galli, MD, Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Personal fees) Louis Yi Ann Chai, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Devi SenGupta, MD, Gilead Sciences Inc. (Employee, Shareholder) Robert H. Hyland, MD, Gilead Sciences Inc. (Employee, Shareholder) Hongyuan Wang, PhD, Gilead Sciences Inc. (Employee, Shareholder) Lijie Zhong, PhD, Gilead Sciences Inc. (Employee, Shareholder) Huyen Cao, MD, Gilead Sciences Inc. (Employee, Shareholder) Anand Chokkalingam, PhD, Gilead Sciences (Employee) Anu Osinusi, MD, Gilead Sciences (Employee) Diana M. Brainard, MD, Gilead Sciences (Employee) Michael Brown, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Ane Josune Goikoetxea, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Mamta Jain, MD, Gilead Sciences Inc. (Scientific Research Study Investigator, Research Grant or Support)GlaxoSmithKline (Advisor or Review Panel member)Janssen (Research Grant or Support)Merck (Research Grant or Support) David Shu Cheong Hui, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Enos Bernasconi, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Christoph Spinner, MD, AbbVie (Advisor or Review Panel member, Other Financial or Material Support, Travel)Bristol-Myers Squibb (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Travel)Janssen (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)MSD (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)Viiv Healthcare (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)
9
Chen, Donald, Liyi Xu, Mary Fortunato-Habib, et al. "1248. Genomic Sequencing and Clinical Data Integration for Next-Generation Infection Prevention." Open Forum Infectious Diseases 5, suppl_1 (2018): S379—S380. http://dx.doi.org/10.1093/ofid/ofy210.1081.
Full textAbstract:
Abstract Background Typical Infection Prevention to detect pathogen transmission in hospitals has relied on observation of (1) uncommon pathogen phenotypes or (2) greater than expected number of pathogen phenotypes in a given timeframe and/or location. Genome sequencing of targeted organisms in conjunction with routine patient geo-temporal information and antibiotic susceptibility data holds promise in identifying transmissions with greater sensitivity and specificity, saving time and effort in reviewing for transmission events. Methods In an on-going genomic sequencing surveillance effort in a tertiary care hospital, drug-resistant clinical isolates from the “ESKAPE” pathogens were routinely sequenced in 2017. In parallel, potential clusters were identified for 2017 through conventional Infection Prevention approaches. Groups identified by their genetic distances along with visualizations on antimicrobial susceptibilities, and patient location histories and dates were displayed in an interactive interface, Philips IntelliSpace Epidemiology (PIE), and reviewed by Infection Prevention. Results Among 656 patients, 1,239 drug-resistant ESKAPE samples were sequenced. Thirty-eight genetically related groups involving 196 patients were identified. Groups ranged in size from two to 44 patients, primarily consisting of VRE and MRSA. Notably, a review of the 38 groups identified 20 groups where the information at hand suggested a concern for transmission. 16 of the 20 were not previously identified by Infection Prevention. Using PIE to review all 38 groups identified from 1 year’s worth of data required 3 hours of time by an Infection Prevention professional, averaging less than 5 minutes per cluster, less than 1 minute per patient, and 11 minutes of review time per actionable opportunity. By conventional means, approximately 23 hours would have been required to review the genomic groups without the aid of the PIE tool. Conclusion The use of PIE’s genomic-defined groups, along with the integrated clinical data platform, allows for a greater ability, certainty, and speed to detect clusters of organisms representing transmission in the hospital setting. Applied prospectively, PIE can detect transmissions sooner than by conventional means for potential patient safety gains and cost savings. Disclosures D. Chen, Philips: Scientific Advisor, Consulting fee. M. Fortunato-Habib, Philips Healthcare: Collaborator and Employee, Salary. A. Hoss, Philips: Employee, Salary. R. Kolde, Philips: Employee, Salary. A. Dhand, Merck: Speaker’s Bureau, Speaker honorarium. Astellas: Scientific Advisor, Consulting fee. R. Sussner, Philips: Scientific Advisor, Consulting fee. J. Carmona, Philips Healthcare: Employee, Salary. B. Gross, Philips Healthcare: Employee, Investigator, Research Contractor, Scientific Advisor and Shareholder, Salary. J. Fallon, Philips Healthcare: Investigator, Research support.
10
Diaz, George, Jose Ramon Arribas, Jose Ramon Arribas, et al. "73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir." Open Forum Infectious Diseases 7, Supplement_1 (2020): S167. http://dx.doi.org/10.1093/ofid/ofaa439.383.
Full textAbstract:
Abstract Background Remdesivir (RDV), a RNA polymerase inhibitor with potent in vitro activity against SARS-CoV-2, is the only treatment with demonstrated efficacy in shortening the duration of COVID-19. Here we report regional differences in clinical outcomes of severe COVID-19 patients treated with RDV, as part of an open-label, randomized phase-3 trial establishing RDV treatment duration. Methods Hospitalized patients with oxygen saturation ≤94%, a positive SARS-CoV-2 PCR in the past 4 days and radiographic evidence of pneumonia were randomized 1:1 to receive 5d or 10d of intravenous RDV. We compared d14 clinical outcomes of patients from different geographical areas, as measured by mortality rates, change in clinical status from baseline (BL) on a 7-point ordinal scale and change in O2 requirements from BL. Based on previous analyses in compassionate use data showing region as an important predictor of outcome, Italy was examined separately from other regions. Results 397 patients were treated with RDV, of which 229 (58%) were in the US, 77 (19%) Italy, 61 (15% in Spain), 12 (3%) Republic of Korea, 9 (2%) Singapore, 4 (1%) Germany, 4 (1%) Hong Kong and 1 (< 1%) Taiwan. BL clinical status was worse in Italy compared to other regions (72% vs 17% requiring high-flow oxygen delivery or higher), and Italian patients were more likely to be male than patients from other regions (69% vs 63%). Overall results showed 5d RDV was as effective as 10d. Mortality at d14 was higher in Italy (18%) compared to all other countries except Italy (7%). Similarly, clinical improvement at d14, measured as ≥2-point increase in the ordinal scale, was lower in Italian patients (39%) compared to all other countries combined (64%). (Fig.1). Figure 1. Change from Baseline in Clinical Status (measured on a 7-point Ordinal Scale) at d14. Conclusion Overall, our results demonstrate significant geographical differences in the clinical course of severe COVID-19 patients treated with RDV. We observed worse outcomes, such as increased mortality and lower rate of clinical improvement, in patients from Italy compared to other regions. Disclosures George Diaz, MD, NO DISCLOSURE DATA Jose Ramon Arribas, MD, Alexa (Advisor or Review Panel member, Speaker’s Bureau, Other Financial or Material Support, Personal fees)Gilead Sciences Inc. (Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau, Other Financial or Material Support, Personal fees)Janssen (Advisor or Review Panel member, Speaker’s Bureau, Other Financial or Material Support, Personal fees)Merck (Advisor or Review Panel member, Speaker’s Bureau, Other Financial or Material Support, Personal fees)Viiv Healthcare (Advisor or Review Panel member, Speaker’s Bureau, Other Financial or Material Support, Personal fees) Jose Ramon Arribas, MD, NO DISCLOSURE DATA Philip A. Robinson, MD, NO DISCLOSURE DATA Anna Maria Cattelan, MD, NO DISCLOSURE DATA Karen T. Tashima, MD, Bristol-Myers Squibb (Research Grant or Support)Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator)GlaxoSmithKline (Research Grant or Support)Merck (Research Grant or Support)Tibotec (Research Grant or Support)Viiv Healthcare (Research Grant or Support) Owen Tak-Yin Tsang, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Owen Tak-Yin Tsang, MD, NO DISCLOSURE DATA Yao-Shen Chen, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Yao-Shen Chen, MD, NO DISCLOSURE DATA Devi SenGupta, MD, Gilead Sciences Inc. (Employee, Shareholder) Elena Vendrame, MD, NO DISCLOSURE DATA Christiana Blair, MS, Gilead Sciences (Employee, Shareholder) Anand Chokkalingam, PhD, Gilead Sciences (Employee) Anu Osinusi, MD, Gilead Sciences (Employee) Diana M. Brainard, MD, Gilead Sciences (Employee) Bum Sik Chin, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Bum Sik Chin, MD, NO DISCLOSURE DATA Christoph Spinner, MD, AbbVie (Advisor or Review Panel member, Other Financial or Material Support, Travel)Bristol-Myers Squibb (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Travel)Janssen (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)MSD (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)Viiv Healthcare (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel) Gerard J. Criner, MD, Gilead Sciences Inc. (Scientific Research Study Investigator)Regeneron (Scientific Research Study Investigator) Gerard J. Criner, MD, NO DISCLOSURE DATA Jose Muñoz, MD, NO DISCLOSURE DATA David Chien Boon Lye, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Chien Boon Lye, MD, NO DISCLOSURE DATA Robert L. Gottlieb, MD, Gilead Sciences Inc. (Scientific Research Study Investigator)
Dissertations / Theses on the topic "Employee advisor"
1
Sin, Philippe. "Le militantisme syndical dans les TPE : proposition d’une typologie de la participation syndicale des conseillers du salarié." Thesis, Paris Est, 2020. http://www.theses.fr/2020PESC0014.
Full textAbstract:
Le militantisme syndical dans les TPE : proposition d’une typologie de la participation syndicale des conseillers du salarié. La littérature s’est jusqu’ici largement intéressée au militantisme syndical dans les grandes entreprises. Cette étude cherche l’enrichir en tentant de comprendre la construction du militantisme syndical des conseillers du salarié dans les très petites entreprises en France, une analyse jusqu’ici absente à notre connaissance. Pour cela, elle s’appuie sur 132 entretiens semi-directifs réalisés auprès de conseillers du salarié, de représentants des cinq principales organisations syndicales représentatives (CGT, CFDT, FO, CFECGC et CFTC), des organisations patronales ainsi que de l’Etat. En mobilisant la littérature sur la participation syndicale et sur le job crafting, l’étude dégage trois profils de militantisme dans le contexte des très petites entreprises : le « bon soldat », le « défenseur des droits » et le « combattant sociétal ». L’étude met en exergue la mobilisation du processus de job crafting par les conseillers du salarié pour construire leur militantisme syndical dans les très petites entreprises. Ils gèrent les ressources et les demandes pour construire une nouvelle participation syndicale et prolongent leur militantisme dans de nouveaux environnements. L’étude montre également que le militantisme syndical dans les très petites entreprises évolue vers des relations plus individualisées avec les salariés, une plus grande autonomie et une professionnalisation croissante des activités<br>Trade union militancy in VSEs: proposal for a typology of trade union participation of employee advisersThe literature has so far focused largely on union activism in large corporations. This study seeks to enrich it by attempting to understand the construction of union militancy of employee advisers in very small companies in France, an analysis that has so far been lacking to our knowledge. It is based on 132 semi-structured interviews with employee advisers, representatives of the five main representative trade union organizations (CGT, CFDT, FO, CFECGC and CFTC), employers' organizations and the State. By mobilizing the literature on union participation and job crafting, the study identifies three profiles of activism in the context of very small businesses: the "good soldier", the "rights defender" and the "societal fighter". The study highlights the mobilization of the job crafting process by employee advisers to build their union activism in very small companies. They manage resources and demands to build new trade union participation and extend their activism into new environments. The study also shows that union activism in very small firms is evolving towards more individualized relations with employees, greater autonomy and increasing professionalization of activities
2
Bergström, Jesper, and Andreas Gustafsson. "Employee motivation underexternal control : A study of financial advisors at large Swedish firms." Thesis, Internationella Handelshögskolan, Högskolan i Jönköping, IHH, Företagsekonomi, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-27008.
Full textAbstract:
Background – Due to the increased complexity of the Swedish financial market, the increased demand for financial services and the increased number of financial advisors, the role of financial advisors is important on the financial market. The external control from Finansinspektionen has been increased in order to eliminate rogue advisors and this type of control often affects employees’ motivation in a negative way. Because of the important role financial advisors have on the financial market, it is essential that they are motivated in order to perform well in their profession. Purpose – The purpose of this study is to investigate how the external control affects the work motivation of financial advisors and how motivational factors could be used when designing a management control system in a context characterized by high external control. To answer this purpose, this thesis answers these following three research questions: What do financial advisors perceive to be the most effective motivational factors? How does the external control influence the motivation of financial advisors? How could the work be designed to maximize the motivation of financial advisors? Method – In order to fulfill the purpose of this study, we have a qualitative approach were we conducted ten semi-structured interviews with financial advisors. The financial advisors are working at two large Swedish financial advisory companies. Findings/Conclusion – After analyzing the empirical data, with relevant theories, interesting findings were made. In general, the external control from Finansinspektionen is interpreted as unmotivating by financial advisors. To counter this, it is important that the employers invest resources to develop IT-systems that minimize the time spent on these work tasks. The administrative work, which arises from the external control, would become more effective and not so time consuming. The management control systems must be designed so that they maximize the motivation of the advisors. Employers must also use correctly designed reward systems in order to have motivated employees. Practical Implications – This study contributes to important findings for managers in Swedish financial advisory companies. Since the management control systems could be designed in another way to maximize the motivation of the financial advisors, this study is an important contribution to the financial sector, where the financial advisors operate.
3
Lawrie, Joshua D. "The effectiveness of the Multicultural Advisor Program at Ball State University." Virtual Press, 2004. http://liblink.bsu.edu/uhtbin/catkey/1285591.
Full textAbstract:
Training staff to better meet the needs of a diverse study body is an important component of housing and residence life programs. This study at Ball State University identified the role and effectiveness of the Multicultural Advisor Program and provides suggestions on how to improve. Six focus groups allowed the researcher to explore the Multicultural Advisor Program from Resident Assistants, Multicultural Advisors, Hall Directors, and students perspectives during fall 2003 semester.<br>Department of Educational Leadership
4
Siming, Linus. "Private equity and advisors in mergers and acquisitions." Doctoral thesis, Handelshögskolan i Stockholm, Finansiell Ekonomi (FI), 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:hhs:diva-947.
Full textAbstract:
This doctoral thesis contains three empirical research papers that center on the topics of private equity and the role of advisors in mergers and acquisitions. "Your Former Employees Matter: Private Equity Firms and Their Financial Advisors” is a study of how social networks that are formed by previous employment relations affect private equity firms’choice of financial advisors. A financial advisor is more likely to advice on a transaction if a former employee is one of the private equity professionals who constitute the deal team for the particular transaction. In turn, information and deals are sourced to private equity firms from sell-side financial advisors within the previous employment network. "Dual Role Advisors and Conflicts of Interest” focuses on the potential conflicts of interest that may arise when an advisor to a firm targeted in a merger or acquisition is simultaneously involved in financing the bidder. Overall, the results suggest that investment banks in these situations may not have fulfilled their obligation of obtaining the highest possible price on behalf of the seller. "Private Equity Firms and Quick Flip Sales” examines the particulars of quick flip investments and three hypotheses that may explain their prevalence. Private equity firms typically are long term investors, but occasionally exits take place in less than 18 months. Results point to that such quick flips may partly be due to conflicting interests between the limited and general partners.<br><p>Diss. Stockholm : Handelshögskolan, 2010. Sammanfattning jämte 3 uppsatser</p>
5
Dang, Tung, and Per Granberg. "Finansiella rådgivare : en studie av faktorer som kan påverka en finansiell rådgivare." Thesis, Högskolan Kristianstad, Sektionen för hälsa och samhälle, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-15754.
Full textAbstract:
Finansiella rådgivare är en yrkesgrupp som ofta beskrivs hamna i en svår position mellan sin arbetsgivare och kunden. Arbetsgivaren kan sätta press på att sälja produkter, medan kunder eftersträvar att få en lämplig rådgivning som är anpassad utifrån kundens förutsättningar. Få studier har studerat hur olika finansiella rådgivare tänker och agerar i en rådgivningssituation mellan de två parterna, samt även hur rådgivarens professionalism påverkar. Vi skapade därför en modell som belyser hur arbetsgivare, professionalism och kundvärde påverkar en finansiell rådgivare. Syftet med denna studie är att skapa förståelse om hur faktorer från arbetsgivaren, professionalism och kundvärde påverkar finansiella rådgivares agerande utifrån rådgivarens olika individuella egenskaper. Teorierna som används i studien är nära relaterade till vad som kan påverka och förklara en finansiell rådgivares agerande. Agentteorin används för att visa på svårigheten i relationen rådgivare har till sina kunder och sin arbetsgivare. Teorin förklarar även hur belöningssystem används för att påverka finansiella rådgivare till att agera enligt arbetsgivarens önskningar. Metoden som användes för att erhålla data var först en förstudie med två intervjuer, som användes för att få information inför skapandet av studiens undersökningsmodell. Därefter användes en kvantitativ metod i form av webbenkäter som skickades ut till 348 finansiella rådgivare, vilka ligger till grund för studiens empiriska data. Slutsatsen visade att det existerar ett samband mellan rådgivare med lite erfarenhet, ung ålder, och till viss del även kvinnor vad gäller att känna sig pressade av arbetsgivaren. Erfarna finansiella rådgivare agerade mer utifrån kundvärde och värderar sin professionalism högre. Framtida forskning kan göra en kvalitativ studie som grundligt undersöker om studiens resultat är samma och utforska om det existerar fler faktorer inom undersökningsmodellen som kan påverka en finansiell rådgivare.<br>Financial advisors are a profession that is viewed as having a difficult position between their employer and the costumer. This position is a result of the employer wanting the financial advisor to create profitability, meanwhile, the customer on the other hand is looking for advice that is best suited for them. Few studies however, have explored how different financial advisors think and act between these two factors, also professionalism is a factor. We have therefore in this study, created a model that emphasizes key qualities in each factor. The purpose of this study is to create a better understanding about how financial advisors are effected by factors from the employer, their professionalism and costumer value. The theories used in this study are related to what might affect and explain financial advisor's behavior in their working situation. Agency theory is used to show the difficulty for an advisor in the relationship between clients and employers. The reward system theory is used to explain how employers can control financial advisors. The method used to obtain data was first through a preliminary study with two interviews. Then we used a quantitative approach in the form of surveys that were sent to 348 financial advisers. This data was then analyzed in SPSS. The conclusion shows that there is a link between advisors with little experience, young age, and to some extent gender to feel pressured by their employer. Experienced financial advisors acted more towards customer value and value their professionalism higher. Future research can make a qualitative study about the same subject, but explore it more in detail and examine if there are new factors that can exist in the model. They can also investigate if a qualitative study will result in the same as our study.
6
Wu, Rong-feng. "The perception of entry level skills among employers, training advisers and trainees in selected occupations in England and Wales and in Taiwan." Thesis, Cardiff University, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.301794.
Full text
7
Yates, Samuel W. "Advisory Firm Employee Ownership and Performance in Separately Managed Accounts." 2017. http://scholarworks.gsu.edu/bus_admin_diss/77.
Full textAbstract:
I describe in detail the structure of separately managed accounts (SMAs) and how those accounts compare to and differ from mutual funds and hedge funds. I then examine how employee ownership of advisory firms — that is, firms in which employees have partnership or stock interests — affects the performance, idiosyncratic risk, and R-square of each firm’s SMA portfolios. In testing 14,484 different portfolios from more than 1,100 different advisory firms from 1995 to 2015, I find that SMAs at firms with employee ownership outperform SMAs at firms without it. The greatest impact is in the 25–50% employee-ownership range. Positive returns, risk, and all decrease as employee ownership increases beyond 50%, but SMA performance levels remain above those of firms in which the portfolio manager has no employee ownership. I also find that the Sharpe ratio is negatively related to employee ownership, reflecting a deterioration of risk-adjusted returns at higher employee-ownership levels. These results suggest both that the presence of advisor employee ownership is a significant, positive indicator for SMA performance and that those advisory firms assume more idiosyncratic risk to achieve these higher returns. For investors, my results show that employee ownership of advisory firms can be used as a differentiating factor to aid them in making SMA choices between portfolios with otherwise similar characteristics.
8
Grübmeyer, Sonja Felecitas. "Quiet activists environmental values and value adjustment in environmental policy advisors /." 2007. http://adt.waikato.ac.nz/public/adt-uow20080131.105404/.
Full text
9
"A comparison of management and financial advisors' perceptions of performance motivators in the long term insurance industry." Thesis, 2008. http://hdl.handle.net/10210/297.
Full textAbstract:
Today’s organisation competes in a fast-moving global marketplace. With technological developments, global communications and demanding customers driving increased competition in most sectors, organisations cannot afford to stand still for long (Holbeche, 2004:32). They exist only when their products and services are sold, and salespeople are usually one of the most important elements of making this happen. Organisations’ fiscal health depends on their ability to drive revenue, but without mastering sales management, revenue can quickly decline. Salespeople need to concentrate on sales, not on responsibilities that pull them in different directions (Bailor, 2004:53). According to Clarke (1998:29), for any company to succeed, the various departments must co-ordinate their efforts and work together. The sales team relies on other departments for support; without sales every other department is worthless. The method of selling has also changed and the days of salespeople carrying briefcases overstuffed with brochures and knocking on every door they can find to drum up interest in their organisations’ products are waning. Today’s professional salespeople co-ordinate the resources of their companies to help solve customers’ problems (Weitz et al, 2004:5). For organisations to succeed in this new environment the right organisational climate is vital to create high performance. This is about making the most of employee talents and accountabilities, and managing performance in ways which unleash, rather than constrain, employee potential (Holbeche, 2004:32). 2 The Long Term Insurance Industry in South Africa had to deal with the changing environment and the introduction of the Financial Advisor Intermediary Service Act of 2002 (FAIS). The traditional principles of successful sales are being challenged in a changing South African insurance industry. Sales managers must rethink their philosophies as the Financial Advisory Intermediary Act (37/2002) regulates the rendering of certain financial advisory and intermediary services to clients and provides for matters incidental thereto. Sales managers can no longer simply motivate financial advisors to achieve targets but should also ensure that all new business is compliant and falls within the new legislation. According to Natenberg (2004:1), sales managers must have a purpose to cope with the added challenges and demands because success comes from purpose. Until a sales manager or financial advisor recognises what needs to be accomplished, there will be a lack of motivation necessary to accomplish anything. Financial advisors burn out easily because they cannot visualise the pot of gold at the end of the rainbow. Everyone wants a driven, highperformance sales team. However, not all sales leaders know how to achieve that. The problem could be motivation. Many sales managers see money as the answer to their motivational problem but money is not everything. For all their commitment to keep salespeople inspired, sales managers would do well to stop and consider the simple things their financial advisors desire. Only then might sales managers be able to craft programmes or work situations in which sales people can thrive (Gilbert, 2003:30). “Too often people let life pass them by. They try hard to achieve something, but when they do, they ask, “Is this all there is to it?” That is because they never 3 take a moment to enjoy how monumental their achievements are. When you accomplish what you set out to do, be proud” (Natenberg, 2004:1).<br>Prof. Chris Jooste
10
NECHVÁTALOVÁ, Vladimíra. "Tranzitní program - prevence nezaměstnanosti absolventa." Doctoral thesis, 2008. http://www.nusl.cz/ntk/nusl-49442.
Full textBooks on the topic "Employee advisor"
1
Sullivan, Frederick L. Recruiting an employee without recruiting a lawsuit: Successful techniques for compliance in the hiring process : the supervisor's advisor on lawful and effective hiring. Sullivan, Hayes & Quinn, 2004.
Find full text
2
Covey, Anne. The workplace law advisor: From harassment to discrimination policies to hiring and firing guidelines : what every manager and employee needs to know. Perseus Pub., 2000.
Find full text
3
Board, Canada Treasury, ed. Non-Represented Employee Advisors Program. The Program, 2001.
Find full text
4
Reilly, Thomas F. An advisory on vacation policies. Office of the Attorney General, Fair Labor and Business Practices Division, 1999.
Find full text
5
104 frequently asked questions about staffing management: With answers from SHRM's knowledge advisors. Society for Human Resource Management, 2014.
Find full text
6
John, Kruse. Self employed and debt: Notes for money advisers. 2nd ed. National Money Advice Training Unit, Money Advice Services, 1991.
Find full text
8
Collison, Jessica. Employer-sponsored investment advice: Survey report. SHRM Research Dept., 2004.
Find full text
9
(Firm), Vault, ed. Vault guide to the top 25 investment management employers. 2nd ed. Vault, 2008.
Find full text
10
Thomas, Kibling, and Legal Action Group, eds. Employment law: An advisers' handbook. 5th ed. Legal Action Group, 2003.
Find full textBook chapters on the topic "Employee advisor"
1
von Gaudecker, Hans-Martin, and Bettina Siflinger. "Labor Supply and Well-Being During the Early Stages of the COVID-19 Crisis in the Netherlands: Lessons from Microdata." In The New Common. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65355-2_10.
Full textAbstract:
AbstractLike many other countries, the Netherlands shut down large parts of economic and social life in the spring of 2020 in response to the COVID-19 pandemic. Between late March and early May, schools and childcare facilities as well as restaurants, cafes, and bars were shut down; contact-related occupations were closed; gatherings were prohibited; and employees were advised to work from home as much as possible. While these regulations represented a sharp cut in individuals’ personal lives, they were more relaxed in the Netherlands than in many other European countries. At the same time, the Netherlands has enacted large-scale economic relief programs.This chapter gives an overview of how labor supply and well-being have changed in the Netherlands in the early stage of the COVID-19 pandemic. We show that changes in the labor market have affected different groups of people differently and we discuss reasons for these differences. In addition, we illustrate how the consequences of the lockdown have altered the well-being of Dutch workers.
2
Lentferink, Aniek, Louis Polstra, Martijn de Groot, Hilbrand Oldenhuis, Hugo Velthuijsen, and Lisette van Gemert-Pijnen. "The Values of Self-tracking and Persuasive eCoaching According to Employees and Human Resource Advisors for a Workplace Stress Management Application: A Qualitative Study." In Persuasive Technology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-78978-1_13.
Full text
3
"Hospital Fringe Benefits Plans and Stock Options: Understanding Employer and Employee Perspectives." In Comprehensive Financial Planning Strategies for Doctors and Advisors. Productivity Press, 2014. http://dx.doi.org/10.1201/b17809-17.
Full text
4
Ingels, Daniel J., Kathryn E. Keeton, and Christiane Spitzmueller. "Writing Organizational Survey Items That Predict What Matters in Organizations." In Employee Surveys and Sensing. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190939717.003.0012.
Full textAbstract:
Organizational surveys are essential tools for gathering data in 21st-century organizations. This chapter provides a practitioner-oriented guide to developing survey content and items. In this chapter, the authors highlight the need to first determine highly specific survey project goals and deduce broad survey content domains based on those goals. They advise practitioners to build close relationships with employees and line managers to develop short survey tools that are organizationally relevant and predictive of organizational outcomes of interest (i.e., customer satisfaction, employee retention). Based on extant research evidence around item and scale development, they discuss response formats, survey length considerations, respondent literacy issues, and cultural as well as language considerations relevant to survey development. They conclude with ethical considerations and a brief summary.
5
Lockwood, Alan H. "Economic Considerations of Climate Change and Health." In Heat Advisory. The MIT Press, 2016. http://dx.doi.org/10.7551/mitpress/9780262034876.003.0009.
Full textAbstract:
Economics govern the relationship between what could be done and what is actually done. A fundamental rule of public health posits that it is medically and economically desirable to prevent rather than to treat an illness. Heat leads to more deaths than any weather-related cause. In the July 2006 California heat wave there were over 16,000 excess emergency room visits and 1,100 hospitalizations. In Washington, there were 3.1 heat-related workman’s compensation claims per 100,000 full time employees. In India the economic burden of dengue is over one billion dollars per year. Puerto Rican data suggest it is the most important and costliest vector-borne disease. Property loss and burdens associated with the production of climate change refugees add to the cost of rising sea level. It’s no surprise that careful studies in the US show that those with the highest social vulnerability will be the most seriously affected. Agriculture will suffer: the 2012 megadrought cost around $30 billion. Economists estimate that heat-related increases in crime will cost each US citizens between $20 and $30 per year by the end of the century.
6
Peng, Jianping, and Jing ("Jim") Quan. "Social Networks and Employee Knowledge Sharing and Performance." In Knowledge Discovery, Transfer, and Management in the Information Age. IGI Global, 2014. http://dx.doi.org/10.4018/978-1-4666-4711-4.ch004.
Full textAbstract:
In this chapter, the authors investigate the correlation between characteristics of the four social networks and employee task and contextual performance. The chapter focuses on the degree centrality and betweenness centrality of the four social networks (Job Advisory, Work Discussion, Friendship and Email Networks) of a Chinese state-owned enterprise as well as the individual attributes of knowledge sharing behavior and IT capability. The findings of this research are 1) employee contextual performance is uncorrelated with the network characteristics; 2) it is significantly and positively correlated with knowledge sharing behavior, but significantly and negatively correlated with individual IT capability, and 3) task performance is correlated, both positively and negatively, with various network characteristics, but not with knowledge sharing behavior and individual IT capability. In addition to discussing the cultural dimension of these results, the authors draw theoretical and managerial implications based on our research framework and findings.
7
Peng, Jianping, and Jing ("Jim") Quan. "Social Networks and Employee Knowledge Sharing and Performance." In Business Intelligence. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-4666-9562-7.ch082.
Full textAbstract:
In this chapter, the authors investigate the correlation between characteristics of the four social networks and employee task and contextual performance. The chapter focuses on the degree centrality and betweenness centrality of the four social networks (Job Advisory, Work Discussion, Friendship and Email Networks) of a Chinese state-owned enterprise as well as the individual attributes of knowledge sharing behavior and IT capability. The findings of this research are 1) employee contextual performance is uncorrelated with the network characteristics; 2) it is significantly and positively correlated with knowledge sharing behavior, but significantly and negatively correlated with individual IT capability, and 3) task performance is correlated, both positively and negatively, with various network characteristics, but not with knowledge sharing behavior and individual IT capability. In addition to discussing the cultural dimension of these results, the authors draw theoretical and managerial implications based on our research framework and findings.
8
Blackburn, Blandina, and Patrick Bose. "Women’s health and other gender issues at work." In Fitness for Work. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198808657.003.0008.
Full textAbstract:
This chapter describes occupational health perspectives on women’s health at work. It looks at known physical and anticipated psychological symptoms of gynaecological and obstetric disorders and gender dysphoria manifested in a range of symptoms that have an impact on work health and performance. It advises on possible adjustments and applicable legal requirements where relevant. Pregnancy and menopause are separate headings as they are common in the workplace, as more women are working, and working for longer. The adjustments to help the employee with such issues at work are in order to acknowledge and normalize these issues, while maintaining good health and performance at work. New additions include infertility and gender dysphoria, and their management in the workplace. Risk assessments in different work scenarios are crucial in order to advise on adjustments. This chapter is written for qualified, trained occupational health personnel, but can be used by other clinicians and interested parties.
9
Leisink, Peter, Lotte B. Andersen, Christian B. Jacobsen, Eva Knies, Gene A. Brewer, and Wouter Vandenabeele. "Conclusion." In Managing for Public Service Performance. Oxford University Press, 2021. http://dx.doi.org/10.1093/oso/9780192893420.003.0016.
Full textAbstract:
The concluding chapter synthesizes the insights and gives a comprehensive answer to the volume’s overall question. It sets directions for future research and discusses implications for public organizations’ practice. There is ample evidence that management contributes to performance, both directly and indirectly, through influencing employees’ (public service) motivation, organizational commitment, and job performance. There is also evidence that management contributes to employee outcomes, both positive, such as their job satisfaction and employability, and negative, such as stress and burnout. The chapter reflects critically on the state of public management research and outlines four key issues for future research: (1) work toward an integrated theoretical framework; (2) develop more comprehensive theoretical models; (3) pay attention to the public sector context; and (4) increase methodological rigor. The chapter contends that public management–performance research remains relevant in the era of inter-organizational networks and co-production, if and when studies pay explicit attention to the public sector context and to the frontline employees involved in service production. The chapter advises public organizations to invest in service provision policies that fit the organizational mission and create the conditions for their implementation by frontline managers who can help public employees create public value.
10
Howard, Gillian S. "Legal aspects of fitness for work." In Fitness for Work. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198808657.003.0002.
Full textAbstract:
This chapter looks at the statutory, contractual, and case law aspects of sickness absence and assessing fitness for work. It covers the role an occupational health practitioner/occupational health adviser plays in disability discrimination cases, assessing whether the disability fits the statutory definition and what reasonable adjustments could be recommended. It also covers the role of the occupational health practitioner/adviser in assessing the short-term, persistent, irregular attender and the chronic or long-term sick case. This chapter also covers the role of the occupational health practitioner in cases of malingering. Precedents, model letters, forms, and policies are also included in this chapter, which are relevant for the employer as well as the occupational health practitioner and occupational health adviser.
Conference papers on the topic "Employee advisor"
1
Starr, Patrick J., and Sylvia Stevenson. "Accelerating the Iterative Process in Design: An Experimental Evaluation of a Computer Based Expert Advisor." In ASME 1991 Design Technical Conferences. American Society of Mechanical Engineers, 1991. http://dx.doi.org/10.1115/detc1991-0056.
Full textAbstract:
Abstract This work explores whether the assistance provided by an Expert Advisor System actually allows a knowledgeable designer to obtain results faster when engaged in a complex trial and error search process. The process is the adjustment of parameters of a discrete event simulation of a manufacturing system in order to achieve certain design specifications. Designed experimentation is employed with human subjects performing tasks with and without the Expert Advisor.
2
Bryan, April, Patricia Brackin, and Wayne Sanders. "Evaluating Lifelong Learning." In ASME 2009 International Mechanical Engineering Congress and Exposition. ASMEDC, 2009. http://dx.doi.org/10.1115/imece2009-12638.
Full textAbstract:
One of the required ABET outcomes is “a recognition of the need for, and an ability to engage in lifelong learning.” Although students must demonstrate this recognition and ability at graduation, data from alumni can strengthen a program’s assertion that its graduates actually engage in lifelong learning. Several strategies for demonstrating lifelong learning are presented and discussed. In addition, a case study from the Mechanical Engineering Department at Rose-Hulman Institute of Technology is presented. For the case study, several assessment instruments were used: an alumni survey, employer focus groups, an Advisory Board survey, and feedback from senior students. Each component will be discussed, results will be presented, and conclusions will be drawn. The alumni survey was made via the internet. The 760 respondents included graduates from the 1940s through the 2000s. Respondents were asked to indicate the number of additional courses or workshops that they had taken and whether or not they had received any additional degrees. Furthermore, respondents were asked to rate the importance of lifelong learning to their current job. In addition, they were asked to rate how well Rose had prepared them for lifelong learning. Employer perspective was gained through focus groups and the advisory board. Companies who were present at career fairs were asked to answer questions about Rose graduates in general. The ME Advisory Board contains members from institutions who are major employers of our graduates. Advisory board members gave feedback based on their knowledge of graduates’ performances. As in the alumni survey, both groups were asked to rate the importance of lifelong learning, along with how well Rose prepared them. Finally graduating seniors were asked to rate how important they felt lifelong learning would be in their careers. In addition, they were asked how well prepared they thought they were. All groups surveyed rated the ability to continue to learn and educate one’s self as being important, and all groups felt that RHIT graduates met the required standard.
3
Elder, G. Gary, Clark W. Mycoff, Gregory Gerzen, Robert K. Perdue, Edward A. Ray, and Warren H. Bamford. "Decision Advisor for Multi-Component Management of Alloy 600 Degradation Issues at the Exelon Braidwood and Byron Nuclear Power Plants." In ASME 2005 Pressure Vessels and Piping Conference. ASMEDC, 2005. http://dx.doi.org/10.1115/pvp2005-71762.
Full textAbstract:
This paper describes how the Westinghouse Decision Advisor Process was employed to develop and quantitatively evaluate the financial merits of alternative strategies to address Alloy 600 (& 82/182) degradation issues at the higher-susceptibility locations throughout four Exelon Generation Company nuclear power units. The objective was to help Exelon focus its resources over both locations and time. Recommendations were also provided for the actions to resolve these issues at these highly susceptible locations. The paper describes the actions taken by Exelon that were supported by this study.
4
Meisyara, S. L., F. D. Saragih, and B. Y. Nugroho. "The Influence of Perceived Organizational Support on Job Satisfaction with Employee Engagement as a Mediating Variable: Study on State Civil Apparatus (ASN) at Secretariat of Presidential Advisory Council." In 1st Paris Van Java International Seminar on Health, Economics, Social Science and Humanities (PVJ-ISHESSH 2020). Atlantis Press, 2021. http://dx.doi.org/10.2991/assehr.k.210304.128.
Full text
5
Padhy, Sisir K., and S. N. Dwivedi. "An Object-Oriented Knowledge-Based System for Assembly of Printed Circuit Boards." In ASME 1991 Design Technical Conferences. American Society of Mechanical Engineers, 1991. http://dx.doi.org/10.1115/detc1991-0068.
Full textAbstract:
Abstract In this paper, Printed Circuit Board Assembly Advisor (PCAAD), an object-oriented knowledge-based system is described. The system aims to aid the designer by suggesting design modifications that will lead to a better design for assembly of the Printed Circuit Boards. To account for the new trends in the printed circuit board production, hybrid technology, i.e. combination of both the through-hole mounted technology and surface mounted technology, is taken into consideration in developing the knowledge base. The assembly constraints as well as various limitations of different techniques and processes are considered to formulate the rules and guidelines. Moreover, a hierarchical rule structure has been employed in creating the knowledge base. Smalltalk-80, the object-oriented language and Surface Percept Description Language (SPDL) are used for the creation of knowledge base. The system provides a high-level user interface and reasoning capability to solve complex problems. It is capable of ranking different designs and suggesting design modifications to the designer during the design stage to eliminate assembly problems in the latter phase of board production.
6
Ramos, Dawson, Pradeepkumar Ashok, Michael Yi, et al. "A Real-Time Probabilistic Slide Drilling Dysfunction Advisory to Assist Remote Directional Drilling Operations." In SPE Annual Technical Conference and Exhibition. SPE, 2021. http://dx.doi.org/10.2118/205984-ms.
Full textAbstract:
Abstract Current slide drilling practices rely heavily on the intuition of the directional drillers to identify and correct drilling dysfunctions. Monitoring numerous dysfunctions simultaneously requires more complex analysis than can be done manually in real-time. There is also currently a big shift towards remote directional drilling. And as such, there is the need for a tool that can, in real-time, diagnose slide drilling dysfunctions accurately and provide advisory to both the remote directional drillers and rig crew. This paper proposes a method for a real-time slide drilling advisory system consisting of a probabilistic model which computes the likelihood that various slide drilling dysfunctions are occurring and an algorithm that determines what corrective action, if any, should be taken as a result. The dysfunction types monitored include buckling, high friction, poor toolface control, stick slip, and bit bounce. The model employs a Bayesian network which uses evidence derived from transient drilling data trends to infer the probability that any of the five considered dysfunctions are taking place. Data trends known to correlate with each dysfunction type are considered simultaneously to ensure that all dysfunction types are monitored continuously. As dysfunction probabilities are calculated, the algorithm cross references them with current drilling parameters and contextual data to determine necessary corrective actions. Corrective actions are output in the form of simple drilling parameter changes shown on a customizable graphical display. The dysfunction beliefs calculated were validated using historical data gathered from North America land drilling operations. For high friction and poor toolface control, known instances of dysfunction were identified using information in drilling logs and expert opinion and used for validation. The validation process resulted in a further refinement of the model. The proposed model along with graphical advisory displays were deployed on rigs in several North American land well drilling operations, as well as in the remote directional drilling center. While there is a lot of prior work that enables identification of rotary drilling dysfunctions in real-time, this is the first method that diagnoses slide drilling dysfunctions in real-time. The approach combines physics based models with a Bayesian network to improve accuracy and robustness in dysfunction detection. Additionally, it considers both real-time drilling data as well as drilling data from the past when diagnosing dysfunctions and facilitates remote directional drilling.
7
Greenwood, Sarah, and Helen Higgs. "Developing Satisfied and Talented Consultants." In The 11th International Conference on Environmental Remediation and Radioactive Waste Management. ASMEDC, 2007. http://dx.doi.org/10.1115/icem2007-7347.
Full textAbstract:
It has been well documented that the ageing, male dominated profile of the workforce in the UK nuclear industry will not support the forecasted nuclear renaissance. Based upon the aspects of age, gender and level of education, there is an existing shortfall in available knowledgeable resource to undertake and manage the extensive new build, operational and decommissioning programmes. The 2005 Nuclear Employers Survey advised the industry to recruit and train more: • young and qualified people. • experienced and qualified people from outside the industry. The future for the UK nuclear industry lies with people in their 20s and 30s. It is essential that not just technical talent but also managerial talent be identified early and that they are nourished and allowed to flourish.
8
Zhang, Jian-hua, Dian-wei Gao, Xin-sheng Liu, and Ke Sun. "Static Analysis of New Type Composite Mono-Piles for Offshore Wind Farm." In ASME 2013 32nd International Conference on Ocean, Offshore and Arctic Engineering. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/omae2013-10583.
Full textAbstract:
The wind energy converters have extreme requirements to lateral deformation and rotation for support structures. Mono-pile, as a popular foundation structure for offshore wind energy towers, must be with sufficient large diameter and deep embedded length to limit the deformation and rotation within the tolerance under cyclic loads. Larger power offshore wind turbine (OWT), bigger pile diameter should be needed. However, large outer diameter pile will lead to difficult construction and high cost. In this study, a new conception of composite mono-pile is presented to decrease the outer diameter of pile. To investigate the structural behavior of composite mono-pile, the finite elements software ABAQUS is employed to analyze and compare with general mono-pile for 1.5 MW OWT under static loads. The numerical results demonstrate that stiffness of composite mono-pile can be improved effectively. Therefore, in same environment condition, composite mono-pipe diameter will be smaller than typical mono-pile, correspondingly, construction difficult and cost will be decreased. In addition, mechanical characteristics of composite mono-pile are analyzed and rational diameter and thickness selection of inserted pile are advised. The research results can provide the reference for practical engineering.
9
Enright, Michael P., R. Craig McClung, Wuwei Liang, Yi-Der Lee, Jonathan P. Moody, and Simeon Fitch. "A Tool for Probabilistic Damage Tolerance of Hole Features in Turbine Engine Rotors." In ASME Turbo Expo 2012: Turbine Technical Conference and Exposition. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/gt2012-69968.
Full textAbstract:
Over the past two decades, the Federal Aviation Administration (FAA) and the aircraft engine industry (organized through the Rotor Integrity Sub-Committee (RISC) of the Aerospace Industries Association) have been developing enhanced life management methods to address the rare but significant threats posed by undetected material or manufacturing anomalies in high-energy rotating components of gas turbine engines. This collaborative effort has led to the release of several FAA advisory circulars providing guidance for the use of probabilistic damage tolerance methods as a supplement to traditional safe-life methods. The most recent such document is Advisory Circular (AC) 33.70-2 on “Damage Tolerance of Hole Features in High-Energy Turbine Rotors.” In parallel with this effort, the FAA has also been funding research and development activities to develop the technology and tools necessary to implement the new methods, including a series of grants led by Southwest Research Institute® (SwRI®). The most significant outcome of these grants is a probabilistic damage tolerance computer code called DARWIN® (Design Assessment of Reliability With INspection). DARWIN integrates finite element models and stress analysis results, fracture mechanics models, material anomaly data, probability of crack detection, and uncertain inspection schedules with a user-friendly graphical user interface (GUI) to determine the probability of fracture of a rotor disk as a function of operating cycles with and without inspection. This paper provides an overview of new DARWIN models and features that directly support implementation of the new AC on hole features. The paper also simultaneously provides an overview of the AC methodology itself. Component geometry and stresses are addressed through an interface with commercial three-dimensional finite element (FE) models, including management of multiple load steps and multiple missions. Calculations of fatigue crack growth (FCG) life employ a unique interface with the FE models, sophisticated new stress intensity factor solutions for typical crack geometries at holes, shakedown modules, a menu of common FCG equations, and algorithms to address the effects of varying temperatures on crack growth rates. The primary random variables are based on the default anomaly distributions and probability-of-detection (POD) curves provided directly in the AC. Fracture risk is computed on a per-feature basis using one of several available computational methods including importance sampling, response surface, and Monte Carlo simulation. The approach is illustrated for risk prediction of a representative gas turbine engine disk. The results can be used to gain a better understanding of the AC and how the problem is solved using the probabilistic damage tolerance framework provided in DARWIN.
10
Sebastiampillai, Joshua, Andrew Rolt, Devaiah Nalianda, Francesco Mastropierro, and Vishal Sethi. "Technical and Economic Viability of an EIS 2050 Geared Open Rotor." In ASME Turbo Expo 2019: Turbomachinery Technical Conference and Exposition. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/gt2019-90290.
Full textAbstract:
Abstract The aviation sector is projected to grow rapidly over the next two decades and beyond. These projections coupled with ever more stringent environmental legislation call for action within the commercial aviation sector to radically reduce greenhouse gas emissions by 2050. It is perceived that by 2050 current state-of the-art direct-drive turbofans will have evolved into geared turbofans and geared open rotor engines for short haul missions. These changes in engine configuration may be attributed to calls from the Advisory Council for Aviation Research and innovation in Europe to dramatically reduce CO2 generation and greenhouse gas emissions by 2050. The geared open rotor architecture is predicted to significantly reduce fuel burn relative to a typical short-range year-2000 aircraft mission, and greatly reduce CO2 emissions per passenger kilometer. Although relative fuel-burn benefits have been estimated in various studies, the economic feasibility of developing the geared open rotor (GOR) engine configuration for potential manufacturers and operators has not been reported. Therefore, this paper describes methodologies employed to estimate the relative fuel burn benefit of a short-range year 2050 GOR engine-aircraft configuration. In addition, it details the financial feasibility of year-2050 short-range engine and aircraft concepts, for manufacturers and operators alike. An overview of the technical specifications of a potential ‘GOR2050’ engine configuration is provided. This paper further describes methods employed to predict the unit cost of a year-2050 engine and aircraft concept that might be offered by the manufacturers, as well as a revenue model for manufacturers in the 2050-timeframe. In order to capture the supplier–customer relationship between the OEMs and their customers, direct operating cost (DOC) and representative revenue models have been constructed for the operators. This paper also analyses the effects that potential future fuel price and taxation policies regarding emissions could have on the operational profitability of such an aircraft and engine combination. Based on a representative set of model inputs, an illustrative test-case for a year-2050 short-haul aircraft and engine combination predicts, with a 50% confidence level, that the minimum number of twin-engine aircraft sales needed to ensure the financial feasibility of the program would be 630 units. Furthermore, with a 50% confidence level, a potential operator could expect an internal rate of return over 7%. The impact of different fuel prices and taxation scenarios are quantified in terms of internal rate of return forecasts.
Reports on the topic "Employee advisor"
1
Yaari, Menahem, Elhanan Helpman, Ariel Weiss, et al. Sustainable Well-Being in Israel. The Israel Academy of Sciences and Humanities, 2021. http://dx.doi.org/10.52873/policy.2021.wellbeing-en.
Full textAbstract:
Well-being is a common human aspiration. Governments and states, too, seek to promote and ensure the well-being of their citizens; some even argue that this should be their overarching goal. But it is not enough for a country to flourish, and for its citizens to enjoy well-being, if the situation cannot be maintained over the long term. Well-being must be sustainable. The state needs criteria for assessing the well-being of its citizens, so that it can work to raise the well-being level. Joining many other governments around the world, the Israeli government adopted a comprehensive set of indices for measuring well-being in 2015. Since 2016, the Israel Central Bureau of Statistics has been publishing the assessment results on an annual basis. Having determined that the monitoring of well-being in Israel should employ complementary indices relating to its sustainability, the Ministry of Environmental Protection, the Bank of Israel, the Central Bureau of Statistics, and Yad Hanadiv asked the Israel Academy of Sciences and Humanities to establish an expert committee to draft recommendations on this issue. The Academy's assistance was sought in recognition of its statutory authority "to advise the government on activities relating to research and scientific planning of national significance." The Committee was appointed by the President of the Academy, Professor Nili Cohen, in March 2017; its members are social scientists spanning a variety of disciplines. This report presents the Committee's conclusions. Israel's ability to ensure the well-being of its citizens depends on the resources or capital stocks available to it, in particular its economic, natural, human, social, and cultural resources. At the heart of this report are a mapping of these resources, and recommendations for how to measure them.
2
McKenna, Patrick, and Mark Evans. Emergency Relief and complex service delivery: Towards better outcomes. Queensland University of Technology, 2021. http://dx.doi.org/10.5204/rep.eprints.211133.
Full textAbstract:
Emergency Relief (ER) is a Department of Social Services (DSS) funded program, delivered by 197 community organisations (ER Providers) across Australia, to assist people facing a financial crisis with financial/material aid and referrals to other support programs. ER has been playing this important role in Australian communities since 1979. Without ER, more people living in Australia who experience a financial crisis might face further harm such as crippling debt or homelessness. The Emergency Relief National Coordination Group (NCG) was established in April 2020 at the start of the COVID-19 pandemic to advise the Minister for Families and Social Services on the implementation of ER. To inform its advice to the Minister, the NCG partnered with the Institute for Governance at the University of Canberra to conduct research to understand the issues and challenges faced by ER Providers and Service Users in local contexts across Australia. The research involved a desktop review of the existing literature on ER service provision, a large survey which all Commonwealth ER Providers were invited to participate in (and 122 responses were received), interviews with a purposive sample of 18 ER Providers, and the development of a program logic and theory of change for the Commonwealth ER program to assess progress. The surveys and interviews focussed on ER Provider perceptions of the strengths, weaknesses, future challenges, and areas of improvement for current ER provision. The trend of increasing case complexity, the effectiveness of ER service delivery models in achieving outcomes for Service Users, and the significance of volunteering in the sector were investigated. Separately, an evaluation of the performance of the NCG was conducted and a summary of the evaluation is provided as an appendix to this report. Several themes emerged from the review of the existing literature such as service delivery shortcomings in dealing with case complexity, the effectiveness of case management, and repeat requests for service. Interviews with ER workers and Service Users found that an uplift in workforce capability was required to deal with increasing case complexity, leading to recommendations for more training and service standards. Several service evaluations found that ER delivered with case management led to high Service User satisfaction, played an integral role in transforming the lives of people with complex needs, and lowered repeat requests for service. A large longitudinal quantitative study revealed that more time spent with participants substantially decreased the number of repeat requests for service; and, given that repeat requests for service can be an indicator of entrenched poverty, not accessing further services is likely to suggest improvement. The interviews identified the main strengths of ER to be the rapid response and flexible use of funds to stabilise crisis situations and connect people to other supports through strong local networks. Service Users trusted the system because of these strengths, and ER was often an access point to holistic support. There were three main weaknesses identified. First, funding contracts were too short and did not cover the full costs of the program—in particular, case management for complex cases. Second, many Service Users were dependent on ER which was inconsistent with the definition and intent of the program. Third, there was inconsistency in the level of service received by Service Users in different geographic locations. These weaknesses can be improved upon with a joined-up approach featuring co-design and collaborative governance, leading to the successful commissioning of social services. The survey confirmed that volunteers were significant for ER, making up 92% of all workers and 51% of all hours worked in respondent ER programs. Of the 122 respondents, volunteers amounted to 554 full-time equivalents, a contribution valued at $39.4 million. In total there were 8,316 volunteers working in the 122 respondent ER programs. The sector can support and upskill these volunteers (and employees in addition) by developing scalable training solutions such as online training modules, updating ER service standards, and engaging in collaborative learning arrangements where large and small ER Providers share resources. More engagement with peak bodies such as Volunteering Australia might also assist the sector to improve the focus on volunteer engagement. Integrated services achieve better outcomes for complex ER cases—97% of survey respondents either agreed or strongly agreed this was the case. The research identified the dimensions of service integration most relevant to ER Providers to be case management, referrals, the breadth of services offered internally, co-location with interrelated service providers, an established network of support, workforce capability, and Service User engagement. Providers can individually focus on increasing the level of service integration for their ER program to improve their ability to deal with complex cases, which are clearly on the rise. At the system level, a more joined-up approach can also improve service integration across Australia. The key dimensions of this finding are discussed next in more detail. Case management is key for achieving Service User outcomes for complex cases—89% of survey respondents either agreed or strongly agreed this was the case. Interviewees most frequently said they would provide more case management if they could change their service model. Case management allows for more time spent with the Service User, follow up with referral partners, and a higher level of expertise in service delivery to support complex cases. Of course, it is a costly model and not currently funded for all Service Users through ER. Where case management is not available as part of ER, it might be available through a related service that is part of a network of support. Where possible, ER Providers should facilitate access to case management for Service Users who would benefit. At a system level, ER models with a greater component of case management could be implemented as test cases. Referral systems are also key for achieving Service User outcomes, which is reflected in the ER Program Logic presented on page 31. The survey and interview data show that referrals within an integrated service (internal) or in a service hub (co-located) are most effective. Where this is not possible, warm referrals within a trusted network of support are more effective than cold referrals leading to higher take-up and beneficial Service User outcomes. However, cold referrals are most common, pointing to a weakness in ER referral systems. This is because ER Providers do not operate or co-locate with interrelated services in many cases, nor do they have the case management capacity to provide warm referrals in many other cases. For mental illness support, which interviewees identified as one of the most difficult issues to deal with, ER Providers offer an integrated service only 23% of the time, warm referrals 34% of the time, and cold referrals 43% of the time. A focus on referral systems at the individual ER Provider level, and system level through a joined-up approach, might lead to better outcomes for Service Users. The program logic and theory of change for ER have been documented with input from the research findings and included in Section 4.3 on page 31. These show that ER helps people facing a financial crisis to meet their immediate needs, avoid further harm, and access a path to recovery. The research demonstrates that ER is fundamental to supporting vulnerable people in Australia and should therefore continue to be funded by government.